An Open‐Label, Multicenter, Phase I, Dose Escalation Study with Phase II Expansion Cohort to Determine the Safety, Pharmacokinetics, and Preliminary Antitumor Activity of Intravenous TKM‐080301 in Subjects with Advanced Hepatocellular Carcinoma

LESSONS LEARNED. TKM‐080301 showed a favorable toxicity profile at the studied dose. TKM‐080301 targeting PLK1 through small interfering RNA mechanism did not demonstrate improved overall survival in patients with advanced hepatocellular carcinoma compared with historical control. Preliminary antitu...

Descripción completa

Detalles Bibliográficos
Autores principales: El Dika, Imane, Lim, Ho Yeong, Yong, Wei Peng, Lin, Chia‐Chi, Yoon, Jung‐Hwan, Modiano, Manuel, Freilich, Bradley, Choi, Hye Jin, Chao, Tsu‐Yi, Kelley, Robin K., Brown, Joanne, Knox, Jennifer, Ryoo, Baek‐Yeol, Yau, Thomas, Abou‐Alfa, Ghassan K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2018
Materias:
Clinical Trial Results
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6656521/
https://www.ncbi.nlm.nih.gov/pubmed/30598500
http://dx.doi.org/10.1634/theoncologist.2018-0838

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6656521/
https://www.ncbi.nlm.nih.gov/pubmed/30598500
http://dx.doi.org/10.1634/theoncologist.2018-0838

Ejemplares similares